The topic today is the safety of full dose rivaroxaban for venous thromboembolism treatment in the elderly or in patients with chronic kidney disease. At the last meeting of the American Society ...

"Thus, the addition of very low-dose anticoagulation with rivaroxaban may represent a ... caution that the proportion of patients who were elderly or had reduced renal function in ATLAS 2 was ...

In addition, patients undergoing TAVR are typically elderly, frail ... treatment strategy including anticoagulation with rivaroxaban at a dose of 10 mg daily as compared with an antiplatelet ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

The study was the first head-to-head trial to compare 2 common options for treatment to prevent recurrent venous thromboembolism. For patients who have experienced a life-threatening blood clot ...

PARIS, France—To head off the risk of device-related thrombus after left atrial appendage (LAA) occlusion, a reduced dose of rivaroxaban may be a viable alternative to dual antiplatelet therapy (DAPT) ...

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran had similar rates of major bleeding compared with low-dose aspirin. In a systematic ...

A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need ...